Your AI-Trained Oncology Knowledge Connection!

Opinion

Video

Challenges in Diagnosing HER2+ Breast Cancer

Author(s):

Joyce O’Shaughnessy, MD,Melinda L. Telli, MD

A panel of experts on breast cancer provide insights on challenges encountered during the diagnosis of HER2+ early breast cancer and discuss the role of immunohistochemistry and FISH testing.

Video content above is prompted by the following question:

  • What are some of the challenges you face in diagnosing HER2+ early breast cancer?

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Melanie A. Sheen, MD
Kelly E. McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA
Coy Heldermon, MD, PhD
Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.
Dr Tolaney on Considerations for Adjuvant CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer
Icro Meattini, ​MD, an associate professor in the Department of Clinical and Experimental Biomedical Sciences at the University of Florence; as well as a clinical oncologist in the Radiation Oncology Unit in the Oncology Department and head of the Breast Unit and Breast Cancer Multidisciplinary Team at Florence University Hospital
4 experts are featured in this series.
Angela Jain, MD
Related Content
Tanya Gupta, MD
March 21st 2025

Selection of Frontline CDK4/6 Inhibitors Hinges on Patient Health Status in HR+/HER2– Metastatic Breast Cancer

Aditya Bardia, MD, MPH, FASCO, professor, Department of Medicine, Division of Hematology/Oncology, director, Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
February 27th 2025

FDA Approval Insights: T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

Vepdegestrant boosts PFS in select ESR1-mutated breast cancer, maintenance OSE2101 combination provides survival benefit in PDAC, and more from OncLive.
March 15th 2025

The OncFive: Top Oncology Articles for the Week of 3/9

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Vepdegestrant in Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 11th 2025

Vepdegestrant Hits PFS End Point in ESR1-Mutated, ER+/HER2– Metastatic Breast Cancer

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 10th 2025

Alisertib Plus Endocrine Therapy Is Under Evaluation in HR+/HER2-Negative Metastatic Breast Cancer